Enhancing the synthetic IQ of CAR T-cells

Recent conceptual as well as technological advances in the areas of molecular immunology, gene transfer and cell processing have fostered increasingly sophisticated translational applications of adoptive T-cell therapy for oncologic disease employing genetically-modified T-lymphocytes. My laboratory’s work focuses on T-cell genetic modification for redirecting antigen specificity to tumors utilizing recent advances not only in the composition and specificity of receptor antigen recognition domains but also the evolution of multifunctional cytoplasmic signaling domains developed for these chimeric antigen receptors (CARs) that provide dual activation and co-stimulatory signaling. My group is also investigating the context of adoptive transfer with respect to the conditioning of the recipient for enhanced T-cell engraftment and expansion, the grafting of CARs on to central memory T-cells having endogenous TCR specificities for viral epitopes to which the host has robust immunity, and the provision tumor microenvironment survival capabilities. The increasingly broad array of genetic manipulations including not only transgene insertion but targeted gene knock out using engineered targeted nucleases such as TALENs and ZFN as well as expression regulatory constructs provides for the creation of synthetic biology of orthogonal immune responses based on gene modified T-cell adoptive transfer. The next decade of advances in this arena will depend on iterative bench-to-bedside back-to-the-bench translational studies capable of sustaining the evolution of these technologies in the context of clinical parameters relevant to the pediatric oncology patient population.

Biography

Michael C Jensen was graduated from the University of Pennsylvania; School of Medicine and completed training in Pediatric Hematology and Oncology at the University of Washington, Fred Hutchinson Cancer Research Center. He is the Sinegal Endowed Professor of Pediatric Hematology-Oncology and Bioengineering at the University of Washington, School of Medicine. He serves as the Founding Director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute. He has been a pioneer in the area of cancer immunotherapy focusing on the genetic engineering of immune system T cells. He is an Inventor on a broad portfolio of patents in this area and leads first-in-man clinical trials of chimeric antigen receptor redirected T-cell immunotherapy. He is also a Scientific Founder of Juno Therapeutics, Inc.

michael.jensen@seattlechildrens.org